Humanigen Inc

Humanigen — KaloBios Pharmaceuticals — Investor Presentation (October 2016)

39 slides from Humanigen's investor presentation, Oct 14, 2016

  1. Slide 1: Advancing Medicines for Neglected and Rare Diseases Through Innovative Business Models

    Advancing Medicines for Neglected and Rare Diseases Through Innovative Business Models OTC: KBIO www.kalobios.com | Corporate Overview - October 14, 2016 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements | Corporate Overview 2 This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and ex

  3. Slide 3: Compelling Investment Opportunity

    Turnaround focused on high-value neglected and rare diseases, including pediatricPipeline of products with multiple potential near- and longer-term catalystsBenznidazole: anticipated streamlined US approval process relying on existing data; potentially eligible for Priority Review Voucher (PRV) that

  4. Slide 4: Two-Pronged Value Model: a Unique Approach To Near-Term Return Propelling Long-Term Value Creation

    Two-Pronged Value Model: a Unique Approach To Near-Term Return Propelling Long-Term Value Creation | Corporate Overview 4 Smart Investment in underappreciated assets Leverage FDA incentives for better efficiency Value Options From multiple FDA catalysts like PRV Value Creation Potential robust comme

  5. Slide 5: Leadership

    Leadership Cameron Durrant, MD, MBAChairman and CEOSenior pharmaceutical and biotech exec, turnaround specialistSenior exec roles at Pharmacia/Pfizer, J+J in US, Merck, GSK in Europe; experience as Exec Chairman, CEO and CFO; CEO roles at three specialty pharma groupsExpertise in anti-infectives, pe

  6. Slide 6: Board of Directors

    Board of Directors Cameron Durrant, MD, MBAChairman | Corporate Overview 6 Ronald Barliant, JDOf Counsel at Goldberg Kohn, extensive experience representing debtors and creditors in complex bankruptcy casesUnited States bankruptcy judge for the Northern District of Illinois 1988 to 2002Dale Chappell

  7. Slide 7: KaloBios Turnaround Momentum Builds: Rising from the Ashes

    KaloBios Turnaround Momentum Builds: Rising from the Ashes | Corporate Overview 7 Funding dead-end, winding down Oct 2015 Martin Shkreli investment late Nov 2015 Shkreli arrest, indictment Dec 2015 Chapter 11 filing Dec 2015 Delisted by Nasdaq Jan 2016 Two new board members Jan 2016 New CEO Mar 2016

  8. Slide 8: Neglected and Rare Disease Assets with Promise to Deliver

    Neglected and Rare Disease Assets with Promise to Deliver | Corporate Overview 8 BENZNIDAZOLEPotential value generator near-term if approvedOral monotherapy with extensive history treating life-threatening infection with 60-day course Preferred treatment for Chagas disease, a neglected tropical dise

  9. Slide 9: Current Pipeline

    Current Pipeline | Corporate Overview 9 Pre-clin Phase I Phase II Phase III Target NDA/BLA Benznidazole (potential PRV)Chagas diseaseAnti-infective LenzilumabCMML Anti-GM-CSF mAb Lenzilumab (potential PRV)JMML (peds) – dependent on interim data in CMMLAnti-GM-CSF mAb Ifabotuzumab (potential PRV)Soli

  10. Slide 10: Anticipated KaloBios Milestones

    Anticipated KaloBios Milestones* Potential FDA Meeting Minutes IND SubmissionPotential Orphan Designation Bioavailability Results CMML P1 interim dataCMML Orphan designationJMML FDA meeting Other potential FDA designations JMML Orphan/RPD designationOther potential FDA designationsJMML P1 first pati

  11. Slide 11: Priority Review Vouchers (PRVs) Create Options For Significant Potential Return

    Priority Review Vouchers (PRVs) Create Options For Significant Potential Return existing PRV programs | Corporate Overview 11 Highest disclosed sale price so far for PRV is $350MM Rare Pediatric Diseases (RPD) Neglected Tropical Diseases (NTD) FDA can award a PRV for eligible products upon approvalM

  12. Slide 12: Two-Year Outlook: We Expect PRV Policy to Remain Generally Stable

    Two-Year Outlook We Expect PRV Policy to Remain Generally Stable Zika virus highlights importance of NTD incentives Post-election, congressional gridlock expected to continueFocus likely on big issues: Medicare Part D, Affordable Care Act May be less political will to change small issuesAdditional P

  13. Slide 13: Benznidazole a potential treatment for Chagas disease

    Benznidazole a potential treatment for Chagas disease | Corporate Overview 13

  14. Slide 14: Chagas Disease

    On FDA list of NTDs eligible for PRVNeglected tropical disease presenting in the US and other nations Currently no FDA-approved treatmentsImmediate need for reliable benznidazole supply in US and abroad CHAGAS disease | Corporate Overview 14 Insect carries the parasite called Trypanosoma cruzi Infec

  15. Slide 15: Benznidazole: the Preferred Treatment Globally for Chagas

    Benznidazole: the Preferred Treatment Globally for Chagas | Corporate Overview 15 40 years of clinical experience, primarily in Latin AmericaUsed in tens of thousands of patients Believed to work by inducing free radicals causing DNA damage within the T. cruzi parasite Efficacy ~60% or more in child

  16. Slide 16: Benznidazole Has Potential for 505(b)(2) New Drug Application

    Benznidazole Has Potential for 505(b)(2) New Drug Application | Corporate Overview 16 Less complexity in overall dossierOur manufacturing validation will be similar to that for a new drug – a competitive advantage 505(b)(2) Hybrid between an ANDA and full NDATo demonstrate efficacy & safety, some da

  17. Slide 17: Benznidazole Strategy Is to Be First to US Approval

    Benznidazole Strategy Is to Be First to US Approval | Corporate Overview 17 SPEEDUtilizing a combination of published literature and existing studies to demonstrate efficacy and safety of benznidazole SAFETYDemonstrating comparable bioavailability and/or bioequivalence with a reference benznidazole

  18. Slide 18: Benznidazole Target Approval Plan

    2016 2017 H1 H2 H1 H2 Manufacturing (CMC) Analytical methods development Drug substance Drug product Stability studies Non-Clinical (Non-Human) Metabolism / PK Toxicity assessment T.cruzi biology Environmental assessment Clinical Summary of relevant clinical studies Right of Reference & data extract

  19. Slide 19: Benznidazole Clinical Profile Treating Chagas Is Well Known

    Benznidazole Clinical Profile Treating Chagas Is Well Known | Corporate Overview 19 Source Study Design Age Follow Up Sample Size Treatment Groups Primary Endpoint Sosa Estani et al 1998 Randomized, double-blind 6-12 48 mo. 106 BNZ 5 mg/kg/d x 60 days (n=55)vs.Placebo (n=51) Negative Serology De And

  20. Slide 20: Lenzilumab a potential pipeline in a product

    Lenzilumab a potential pipeline in a product | Corporate Overview 20

  21. Slide 21: KaloBios Humaneered Platform

    KaloBios Humaneered® Platform Murine segments replaced by human sequences from human donor libraryNew segments have amino acid identity very near to human germ-line segments | Corporate Overview 21 THERAPEUTIC GOALS Proprietary and patented technology platform to engineer antibodies, typically murin

  22. Slide 22: CMML Overview

    High unmet needPatients typically unsuitable for stem cell transplant40-90% patients show hypersensitivity to GM-CSF CMML overview | Corporate Overview 22 Recently classified as separate disease with distinct natural history* Median overall survival rate in months Newly diagnosed US patients per yea

  23. Slide 23: JMML Overview

    No FDA-approved treatmentClear unmet needPotential for a rare pediatric disease PRVGM-CSF hypersensitivity is hallmarkPediatric oncology largely ignored in clinical development JMML overview | Corporate Overview 23 Event-free survival rate at 5 years (with bone marrow transplant) New US cases per ye

  24. Slide 24: Mutations Affect GM-CSF Signaling, Confers Hypersensitivity in Leukemias

    Neutralization of GM-CSF inhibits JAK-STAT and RAS signaling pathways in leukemic cells Mutations Affect GM-CSF Signaling, Confers Hypersensitivity in Leukemias | Corporate Overview 24 Inactivation of the NF1 tumor suppressor gene or oncogenic mutations in NRAS, KRAS2, CBL, or PTPN11. The values in

  25. Slide 25: Lenzilumab Has Strong Potential as an Inhibitor of GM-CSF

    Lenzilumab Has Strong Potential as an Inhibitor of GM-CSF | Corporate Overview 25 Potently decreases effect of GM-CSF, shows potential to kill leukemia cells in pre-clinical studies Encouraging safety profile in multiple studies with >90 patientsPotential FDA Breakthrough Therapy and Rare Pediatric

  26. Slide 26: Strong Correlation Between GM-CSF Sensitivity, CMML / JMML

    pSTAT5 Heat Map showing GM-CSF responsive populations Kotecha et al 2008 Strong Correlation Between GM-CSF Sensitivity, CMML / JMML | Corporate Overview 26

  27. Slide 27: Lenzilumab is a Potent Inhibitor of GM-CSF Function In Vitro

    Lenzilumab is a Potent Inhibitor of GM-CSF Function In Vitro | Corporate Overview 27 Inhibits GM-CSF-dependent Proliferation of Human TF-1 Leukemia Cells Blocks GM-CSF-induced STAT5 Phosphorylation in Human TF-1 Leukemia Cells Source: KaloBios laboratory notebook STAT5 phosphorylation detection in T

  28. Slide 28: Lenzilumab Has an Established Safety Profile in Patients

    Lenzilumab Has an Established Safety Profile in 94 Patients | Corporate Overview 28 Study* Population Objectives Enrollment/Dose Safety Results Phase 1 Single-dose, dose-escalation Healthy adult volunteers Safety/tolerabilityPKImmunogenicity (n=12)3 / 1 mg/kg3 / 3 mg/kg3 / 10 mg/kg3 / placebo Clean

  29. Slide 29: Lenzilumab Holds Niche in GM-CSF

    Lenzilumab Holds Niche in GM-CSF | Corporate Overview 29 Source: Wicks, I. P. & Roberts, A. W. (2015) Targeting GM‑CSF in inflammatory diseases. Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2015.161 GM-CSF Lenzilumab Humanized monoclonal antibody Asthma (moderate to severe) Lenzilumab (400mg) or placebo

  30. Slide 30: Lenzilumab Phase Clinical Evaluation Builds and Transitions from CMML to JMML

    Lenzilumab Phase 1 Clinical Evaluation Builds and Transitions from CMML to JMML PRIMARY OBJECTIVE: Maximum tolerated dose or recommended phase 2 dose; safety and tolerabilitySECONDARY OBJECTIVES: Preliminary efficacy, PK/PD biomarkers Expect consortium or cooperative group-led study of 10-15 sites*

  31. Slide 31: Lenzilumab CMML/JMML Planned Clinical Trial Execution Matrix

    Lenzilumab CMML/JMML Planned Clinical Trial Execution Matrix | Corporate Overview 31 2016 2017 2018 2019 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2019 CMML Phase 1 Dose Escalation Study Phase 1b/2 Expand Single Arm + Combination Study First patient dosed Preliminary safety/activity data Interim analysis ASH ab

  32. Slide 32: Lenzilumab: a Pipeline in a Drug Opportunity

    Lenzilumab: a Pipeline in a Drug Opportunity | Corporate Overview 32 JMML ALPS / RALD Cytokine Release Syndrome AMML RASopathies (e.g. CFC syndrome, Costello syndrome) Noonan Syndrome with PTPN11 CMML CML Plexiform Neurofibroma Pediatric Multiple Sclerosis US ADDRESSABLE POPULATION 325 350 500 600 7

  33. Slide 33: Ifabotuzumab significant potential for partnering and development

    Ifabotuzumab significant potential for partnering and development | Corporate Overview 33

  34. Slide 34: Ifabotuzumab: Several Mechanisms to Lead to Tumor Cell Killing

    Ifabotuzumab: Several Mechanisms to Lead to Tumor Cell Killing, Disruption | Corporate Overview 34 Brain cancer is now #1 killer pediatric cancer, according to CDCPotential in solid tumors, including rare pediatric tumors; PRV potentialEvaluating phase 0/I bio-distribution study in rare solid tumors

  35. Slide 35: Ifabotuzumab Target Affects Cell Positioning, Survival, Tumor Growth

    Ifabotuzumab Target Affects Cell Positioning, Survival, Tumor Growth EphA3Receptor tyrosine kinaseImportant in fetal developmentNot on normal adult tissuesRe-expressed on cancer and certain non-malignant diseasesUpregulated by some chemotherapeutic agents (HMAs, HDACs) and hypoxiaTarget accessible t

  36. Slide 36: Ifabotuzumab Has Four Postulated Mechanisms of Action

    1 2 3 4 Ifabotuzumab Has Four Postulated Mechanisms of Action | Corporate Overview 36 ADCC Mediated Killing of Tumor Cells Direct Apoptosis of Tumor Cells Disruption of Tumor Vasculature through Cell Rounding Anti-fibrotic Effect Ifabotuzumab Ifabotuzumab Ifabotuzumab Ifabotuzumab

  37. Slide 37: Capitalization Summary as of 10/4/16

    Capitalization Summary as of 10/4/16 | Corporate Overview 37 Debt $1.2 million Common Shares Outstanding 14.9 million Stock Options (WAEP $5.82) 2.0 million Warrants (WAEP $14.24) 0.3 million Fully Diluted Shares Outstanding 17.3 million

  38. Slide 38: Demonstrated History of Swift Execution in Challenging Circumstances

    Demonstrated History of Swift Execution in Challenging Circumstances | Corporate Overview 38 JUN JUL AUG SEP OCT Emerge in six months from complex Chapter 11 bankruptcy Lenzilumab Phase 1 trial started Extinguished Martin Shkreli’s stake in the company Current with Securities and Exchange Commission

  39. Slide 39: Summary

    Summary Unique near-term/long-term potential value creation opportunity Thoughtful business strategy that leverages existing U.S. regulatory and development incentivesAttractive asset portfolio with multiple potential milestones and partnering prospectsDeeply committed and focused new management tea

KaloBios Pharmaceuticals — Investor Presentation (October 2016) on 6ix